News Headlines Article

Stanford cancer-fighting spinout to Genentech: ‘Don’t eat me’
San Francisco Business Times

A Peninsula startup focusing on a hijacked “don’t eat me” signal sent by cancer cells to the immune system will work with Genentech Inc. to take an experimental drugs into two clinical trial programs.

Forty Seven Inc., a Menlo Park-based spinout of from the Stanford University labs of Irv Weissman, also said Thursday that it cut a deal with Germany’s Merck KGaA for another study in humans.

The financial value of both deals and how research and development costs will be split wasn’t disclosed by the companies. The deals are the first by Forty Seven with corporate partners. The company raised a $75 million Series B round in October.